Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 2/20 | 0.32 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | VNN1 | O95497 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 2/20 | 0.31 |
| ▸ | KRAS | P01116 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27209353 | 1.00 | DPP4 (0.46) | DPP4SCN9ALTA4HEIF2AK4PDE4B | |
| SCHEMBL3774805 | 0.77 | PIK3CD (0.39) | DPP4ATR | |
| SCHEMBL3772792 | 0.77 | PIK3CD (0.39) | DPP4ATR | |
| SCHEMBL26110419 | 0.74 | HTR1A (0.51) | — | |
| SCHEMBL23138573 | 0.73 | LTA4H (0.34) | DPP4LTA4HEIF2AK4PDE4B | |
| SCHEMBL19370311 | 0.73 | HTR2A (0.41) | DPP4SCN9ALTA4HEIF2AK4PDE4B | |
| SCHEMBL19370310 | 0.73 | HTR2A (0.41) | DPP4SCN9ALTA4HEIF2AK4PDE4B | |
| SCHEMBL18590395 | 0.73 | LTA4H (0.36) | DPP4LTA4HEIF2AK4PDE4B | |
| SCHEMBL16853906 | 0.73 | LTA4H (0.34) | DPP4LTA4HEIF2AK4PDE4B | |
| SCHEMBL18590394 | 0.73 | LTA4H (0.36) | DPP4LTA4HEIF2AK4PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117157299-B | Tricyclic heterocyclic derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20240140954-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2024-05-02 | — | — | US | disclosed |
| EP-1856058-B1 | PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2014-09-03 | — | — | EP | disclosed |
| EP-2044038-B1 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | CORNERSTONE THERAPEUTICS INC (US) | 2014-07-02 | — | — | EP | disclosed |
| US-7759337-B2 | Phthalazine compounds and methods of use | AMGEN INC. (US) | 2010-07-20 | — | — | US | disclosed |
| EP-2044038-A2 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | Cornerstone Therapeutics Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007146066-A2 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | CRITICAL THERAPEUTICS, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20060199817-A1 | Phthalazine, aza- and diaza-phthalazine compounds and methods of use | AMGEN INC. (US) | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199817-A1 | Phthalazine, aza- and diaza-phthalazine compounds and methods of use | DAPK2, CDK2, DAPK1 | DPP4 974/4885SCN9A 4568/4885LTA4H 2049/4885 |
| US-20240140954-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | CYP11B2, SDHA, CYP3A43 | DPP4 1460/4885SCN9A 3184/4885LTA4H 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.